NCT01817751View on ClinicalTrials.gov

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

April 11, 2013

Primary Completion Date

August 27, 2020

Study Completion Date

May 12, 2023

Conditions
GlioblastomaRecurrent Adult Brain NeoplasmMalignant GliomaWHO Grade III Glioma
Interventions
DRUG

sorafenib tosylate

Given by mouth

DRUG

valproic acid

Given by mouth

DRUG

sildenafil citrate

Given by mouth

Trial Locations (1)

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Virginia Commonwealth University

OTHER

NCT01817751 - Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma | Biotech Hunter | Biotech Hunter